Trial · NCT00790933
Results by group1,064
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 1,064
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Vedolizumab 300 mg (UC) | TEAEs | 93 | percentage of participants | |
| Percentage of Participants With One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Vedolizumab 300 mg (CD) | TEAEs | 96 | percentage of participants | |
| Percentage of Participants With One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Vedolizumab 300 mg (UC) | SAEs | 31 | percentage of participants | |
| Percentage of Participants With One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Vedolizumab 300 mg (CD) | SAEs | 41 | percentage of participants | |
| Number of Participants With Markedly Abnormal Safety Laboratory Findings | Vedolizumab 300 mg (UC) | Hemoglobin <= 70 g/L | 16 | participants | |
| Number of Participants With Markedly Abnormal Safety Laboratory Findings | Vedolizumab 300 mg (CD) | Hemoglobin <= 70 g/L | 11 | participants | |
| Number of Participants With Markedly Abnormal Safety Laboratory Findings | Vedolizumab 300 mg (UC) | Absolute Lymphocyte Count <0.5 X 10^9/L | 28 | participants | |
| Number of Participants With Markedly Abnormal Safety Laboratory Findings | Vedolizumab 300 mg (CD) | Absolute Lymphocyte Count <0.5 X 10^9/L | 56 | participants | |
| Number of Participants With Markedly Abnormal Safety Laboratory Findings | Vedolizumab 300 mg (UC) | Leukocytes <2.0 X 10^9/L (Absolute Value) | 1 | participants | |
| Number of Participants With Markedly Abnormal Safety Laboratory Findings | Vedolizumab 300 mg (CD) | Leukocytes <2.0 X 10^9/L (Absolute Value) | 3 | participants | |
| Number of Participants With Markedly Abnormal Safety Laboratory Findings | Vedolizumab 300 mg (UC) | Platelets <75.0 X 10^9/L | 2 | participants | |
| Number of Participants With Markedly Abnormal Safety Laboratory Findings | Vedolizumab 300 mg (CD) | Platelets <75.0 X 10^9/L | 5 | participants | |
| Number of Participants With Markedly Abnormal Safety Laboratory Findings | Vedolizumab 300 mg (UC) | Absolute Neutrophil Count <1.0 X 10^9/L | 9 | participants | |
| Number of Participants With Markedly Abnormal Safety Laboratory Findings | Vedolizumab 300 mg (CD) | Absolute Neutrophil Count <1.0 X 10^9/L | 9 | participants | |
| Number of Participants With Markedly Abnormal Safety Laboratory Findings | Vedolizumab 300 mg (UC) | Prothrombin Time >1.25 x ULN | 42 | participants | |
| Number of Participants With Markedly Abnormal Safety Laboratory Findings | Vedolizumab 300 mg (CD) | Prothrombin Time >1.25 x ULN | 37 | participants | |
| Number of Participants With Markedly Abnormal Safety Laboratory Findings | Vedolizumab 300 mg (UC) | ALT >3.0 x ULN | 30 | participants | |
| Number of Participants With Markedly Abnormal Safety Laboratory Findings | Vedolizumab 300 mg (CD) | ALT >3.0 x ULN | 47 | participants | |
| Number of Participants With Markedly Abnormal Safety Laboratory Findings | Vedolizumab 300 mg (UC) | AST >3.0 x ULN | 35 | participants | |
| Number of Participants With Markedly Abnormal Safety Laboratory Findings | Vedolizumab 300 mg (CD) | AST >3.0 x ULN | 34 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00790933/results